Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EPS (Weighted Average and Diluted) (2021 - 2023)

Historic EPS (Weighted Average and Diluted) for Candel Therapeutics (CADL) over the last 3 years, with Q4 2023 value amounting to -$0.38.

  • Candel Therapeutics' EPS (Weighted Average and Diluted) fell 12352.94% to -$0.38 in Q4 2023 from the same period last year, while for Dec 2023 it was -$1.3, marking a year-over-year decrease of 10312.5%. This contributed to the annual value of -$1.74 for FY2024, which is 3282.44% down from last year.
  • Candel Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.38 in Q4 2023, which was down 12352.94% from -$0.29 recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.51 in Q4 2021 and a low of -$1.46 during Q2 2021
  • For the 3-year period, Candel Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.33, with its median value being -$0.3 (2022).
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 9041.1% in 2022, then crashed by 90000.0% in 2023.
  • Over the past 3 years, Candel Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at $0.51 in 2021, then tumbled by 133.33% to -$0.17 in 2022, then plummeted by 123.53% to -$0.38 in 2023.
  • Its EPS (Weighted Average and Diluted) stands at -$0.38 for Q4 2023, versus -$0.29 for Q3 2023 and -$0.33 for Q2 2023.